Topics

BMS pulls Opdivo+Yervoy combo in EU for advanced non-small cell lung cancer

07:08 EST 3 Feb 2020 | Pharmafile

Bristol-Myers Squibb has confirmed it has withdrawn its application with the European Commission for its combination of Opdivo (nivolumab) and Yervoy (ipilimumab) for the treatment of advanced non-small cell lung cancer (NSCLC).

The decision was made after the EMA’s Committee for Medicinal Products for Human Use (CHMP) informed the company that the data had submitted was not valid due to a number of “protocol changes” that had been made during the execution of the clinical study which generated them.

read more

Original Article: BMS pulls Opdivo+Yervoy combo in EU for advanced non-small cell lung cancer

NEXT ARTICLE

More From BioPortfolio on "BMS pulls Opdivo+Yervoy combo in EU for advanced non-small cell lung cancer"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Monoclonal antibodies MAbs
Monoclonal antibodies recognise and attach to specific proteins produced by cells.  Types of monoclonal antibodies used to treat cancer cells: Block cell dividing dividing signals Transport cancer drugs or radiation to cancer cells Tr...

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...